- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Hightide Therapeutics Inc.
Headquarters: Shenzhen, Guangdong, China
Website: https://hightidetx.com/
Year Founded: 2011
Status: Public
Industry Sector: HealthTechnology
CEO: Li Ping Liu, PhD, MBA
Number Of Employees: 70
Enterprise Value: $17,390,723
PE Ratio: -2.93
Exchange/Ticker 1: HKEX:2511
Exchange/Ticker 2: N/A
Latest Market Cap: $177,396,543
BioCentury | Jan 12, 2024
Finance
The year of biotech’s recovery
Public Markets Preview: Investors say biotech outperformance in 2024 will hinge on the interest rate environment
BioCentury | Jan 6, 2023
Deals
Jan. 5 Quick Takes: CytomX rebound continues with Moderna deal
Plus: GSK licenses WuXi Biologics bispecific, Acelyrin adds thyroid eye asset via ValenzaBio takeout, HighTide, Metagenomi, Synaffix-Amgen, AstraZeneca and more
BioCentury | Oct 20, 2022
Management Tracks
5AM hires Anna Yaeger as head of public equities
Plus Scripps alum Maricich becomes Ashvattha CMO and updates from Alexion, Rewind, ExeVir and more
BioCentury | Jan 8, 2022
Management Tracks
Totus recruits Singer as first CFO
Plus updates from Pharmaron, Adverum, Azenta, InterVenn and more
BioCentury | Feb 3, 2021
Management Tracks
Lilly Asia’s Li joins AffaMed as president; plus moves at Actimed, Elicio, Life Biosciences, OncoNano, Tollys, HighTide and Patient Square Capital
China-based in-licensing company AffaMed Therapeutics (Shanghai) Co. Ltd. hired Ji Li as president. Li was most recently a venture partner at Lilly Asia Ventures, and prior to that
Items per page:
1 - 5 of 5